By Josh White
Date: Wednesday 08 Mar 2023
(Sharecast News) - Biopharmaceutical company Ovoca Bio announced on Wednesday that it will be disposing of certain Russian assets to the private Russian company Desirix.
By Josh White
Date: Friday 29 Jul 2022
(Sharecast News) - Women's health-focussed biopharmaceutical company Ovoca Bio announced the successful completion of participant enrollment in a phase 2 dose-ranging study assessing 'orenetide' on Friday.
By Josh White
Date: Friday 29 Jan 2021
(Sharecast News) - Biopharmaceutical company Ovoca Bio said on Friday that the first patient has been enrolled in a phase 2 dose-ranging study assessing 'BP-101', which it described as a novel treatment for premenopausal women with hypoactive sexual desire disorder (HSDD) - a condition characterised by a distressing lack or loss of sexual desire.
Currency | UK Pounds |
Share Price | 5.75p |
Change Today | -0.25p |
% Change | -4.17 % |
52 Week High | 14.00 |
52 Week Low | 4.75 |
Volume | 45,206 |
Shares Issued | 88.46m |
Market Cap | £5.09m |
Value |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Price Trend |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Income | ![]() |
---|
Growth | ![]() |
---|
No dividends found |
Time | Volume / Share Price |
10:42 | 45,206 @ 5.60p |
CEO | Kirill Andreyevich Golovanov |
You are here: research